<i><scp>IL</scp>28<scp>B</scp></i> genotype is not useful for predicting treatment outcome in <scp>A</scp>sian chronic hepatitis <scp>B</scp> patients treated with pegylated interferon‐α

Abstract

In the context of a small possible effect size and high frequency in Asian populations, IL28B genotyping is likely to have, at best, limited clinical utility for predicting peg-IFN treatment outcome for CHB patients in the Asia-Pacific region.